SLC5A2 and type 2 diabetes mellitus: This study aims to comprehensively assess the existing controlled trials on SGLT-2 inhibitor therapy for HF and T2DM patients through a meta-analysis approach, aiming to clarify their efficacy and safety, and ultimately provide more comprehensive and scientific evidence to support the treatment of HF and T2DM patients.